Myelofibrosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Myelofibrosis (MF) is a rare chronic BCR-ABL1-negative myeloproliferative neoplasm characterised by progressive bone marrow fibrosis, inefficient hematopoiesis, and short survival. The clinical manifestations of MF include cytopenias, consequent to extramedullary hematopoiesis, splenomegaly, and an array of potentially debilitating abdominal and constitutional symptoms. Dysregulated Janus kinase (JAK)-signal transducer and activator of transcription signaling underlie secondary disease-associated effects in MF, such as myeloproliferative, cachexia, constitutional symptoms, and bone marrow fibrosis. Common fatal complications of MF include transformation to acute leukemia, thrombohemorrhagic events, organ failure, and infections.
- Thelansis' research encompasses both secondary and primary research findings. The incidence of MF ranges from 1.7 to 2.4 per 1,00,000 persons, whereas the estimated prevalence in the USA varies from 3.6 to 5.7 per 100,000 persons.
Thelansis’s “Myelofibrosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelofibrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Myelofibrosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Myelofibrosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment